Who makes Treatment A_Period 3?

Treatment A_Period 3 is developed by JW Pharmaceutical.

What development phase is Treatment A_Period 3 in?

Treatment A_Period 3 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Treatment A_Period 3

JW Pharmaceutical · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	Treatment A_Period 3
Also known as	NA (Not Applicable)
Sponsor	JW Pharmaceutical
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment A_Period 3 CI brief — competitive landscape report
Treatment A_Period 3 updates RSS · CI watch RSS
JW Pharmaceutical portfolio CI